Tekton Research的动态

Multiple Myeloma study results published in the New England Journal of Medicine (NEJM). A huge congratulations to Dr Hanlon Sia and Pindara Private Hospital Clinical Trials & Research Unit on their involvement in the DREAMM-7 and DREAMM-8 Trials. These pivotal studies evaluated the efficacy and safety of alternative treatments for patients with relapsed or refractory multiple myeloma. The results demonstrate significant improvement in patient outcomes, supporting the potential for robust new treatment options. NEJM is the most widely read, cited and influential general medical journal globally, and highlights the exceptional impact of these publications. This is a considerable step forward in patient care, and an incredible achievement for Pindara Private Hospital Clinical Trials & Research Unit and the broader study team. Read both papers published in NEJM here: https://lnkd.in/gHvpXbm3 ? https://lnkd.in/gZBMGGDg #NEJM #ClinicalTrials #RamsayResearch #PindaraPrivateHospital #MultipleMyeloma

This is a very good synopsis on the mismatch between the basis for the proposed LCD policies on CAMPS and what this would yield in terms of patient and financial outcomes. Clinical efficacy data and outcomes can drive policy that will ultimately control costs if cognizant parameters are established.

Continually grateful to be a part of such an innovative , forward thinking, academic research organization. Constantly expanding my experience in a variety of clinical research therapeutic areas, now including cardiovascular disease. Knowing that I am making a truly impactful difference in the lives of others is what will forever push me to move onward and upward in the field of clinical research. #clinicaltrials #cardiovascularesearch #medicine

???Check out our latest article published as a special feature in ACRP - Association of Clinical Research Professionals journal "Clinical Researcher", authored by One2Treat experts Samuel Salvaggio, PhD, Emilie Barré, Sébastien Coppe, PhD and Marc Buyse. This paper presents a compelling argument for the broader adoption of Generalized Pairwise Comparisons (GPC) in clinical research to meet modern healthcare challenges, design patient-centric protocols, and approve patient-centered treatments at a faster pace. ? Key takeaways: - Integrate multiple patient relevant outcomes into a single comprehensive assessment, to better reflect the full spectrum of treatment effects. - Enhance clinical relevance while significantly reducing sample sizes, making trials more efficient and timely. - Successful applications of GPC led to notable FDA approvals in cardiovascular disease. Read the full article for a deeper dive into how GPC can revolutionize clinical research and improve patient outcomes?by bringing a more holistic approach to treatment assessment: https://lnkd.in/epv-i_X9 #ClinicalTrials #PatientCentricity #Innovation

Imagine the future of medicine. No matter what advancements you think of, they aren’t possible without clinical research. Learn how you can make an impact with Clinical Trials For All: https://lnkd.in/gTbHuDvt

Have you ever wondered how new medical treatments are discovered?? The answer lies in clinical trials – a crucial step in the journey from scientific discovery to life-saving treatments. Check out our latest fact sheet below featuring three groundbreaking NIH-funded clinical trials that are paving the way for tomorrow’s treatments. #keepNIHstrong

The Life Improvement Trial (LIFT) has officially begun! Conducting a proper clinical trial and ensuring all logistics are set up takes time, so we are excited to share that Open Medicine Foundation’s Life Improvement Trial (LIFT) has officially launched. Recruitment and screening began in August and the first participants have now been enrolled. Learn more ?? https://lnkd.in/e37AkVD5. What is the LIFT? The LIFT is a double-blind, placebo-controlled clinical trial investigating the effect of low-dose naltrexone (LDN) and pyridostigmine (Mestinon) on functional capacity, physiological response, and the symptoms of ME/CFS. Why conduct this trial? LDN and Mestinon have both shown promise in relieving patients’ symptoms, but there isn’t a lot known about why they might help people with ME/CFS or which people they might help. We know that LDN and Mestinon won’t help everyone, but importantly, the LIFT is designed so the team can try to identify differences between responders and non-responders. Ultimately, if the trial indicates that these drugs can help relieve symptoms of ME/CFS, the study will provide scientific evidence that both doctors and patients can use to support decisions about treatment. We also hope that if we can better understand what makes someone respond positively to either drug, then this information can help guide more personalized treatment plans for patients in the future.

It's 18 months since JCO published the Clinical Practice Gaps paper that delivered the astounding statistic that 64% of patients do not gain access to optimal precision therapies. Diaceutics are hosting a landmark, free-to-attend, summit on May 1st to discuss how all stakeholders can come together to address the economic, policy and operational barriers that are impacting patient lives. I hope you can join us for this important discussion on how together we can shape the future of precision medicine. https://lnkd.in/e8yUFxRB #JoinThePanel #PrecisionMedicine

Reporting even the simplest medical observations with a high level of astuteness is paramount for enhancing patient outcomes and ensuring all medical personnel stay current with their knowledge. By meticulously documenting even seemingly minor details, healthcare providers can uncover crucial insights that may lead to more accurate diagnoses and effective treatments. Our paper, which we proudly present, addresses the significance of this meticulous approach to reporting in medical scenarios. Through our research and findings, we aim to empower healthcare professionals to elevate their reporting standards, ultimately contributing to improved patient care and the continuous advancement of medical knowledge and practices. Please read our article published in the prestigious clinical imaging. https://lnkd.in/extwtDr